<DOC>
	<DOC>NCT02902978</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of a single dose of E6130 in Japanese healthy adult male participants.</brief_summary>
	<brief_title>A Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects</brief_title>
	<detailed_description>This study consists of 8 cohorts, Cohorts 1 to 8. Cohorts 1 to 7 are designed as a single-center, single dose, placebo-controlled, randomized, ascending dose, double-blind study. Cohort 8 is designed as a single-center, single dose, randomized, open-label, two-group, two-period crossover study. Cohort 8 will be initiated after Cohorts 1 to 7 are completed.</detailed_description>
	<criteria>Inclusion Criteria 1. Japanese healthy adult males aged â‰¥20 and &lt;45 years at the time of informed consent who are nonsmokers or able to stop smoking from at least 4 weeks before study drug administration until the posttreatment examination. 2. Has voluntarily consented, in writing, to participate in this study. 3. Has been thoroughly briefed on the conditions for participation in the study, and is willing and able to comply with the conditions. Exclusion Criteria 1. History of surgical treatment that may affect the pharmacokinetics of the study drug at screening. 2. Suspected to have clinically abnormal symptoms or impairment of organ function requiring treatment on the basis of history and complications at screening, and physical findings, vital signs, ECG findings, or laboratory values at screening or baseline. 3. History of drug allergy at screening. 4. Judged by the investigator or subinvestigator to be inappropriate for participation in this study.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>E6130</keyword>
	<keyword>Japanese healthy adult male participants</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>